Hims & Hers Health, Inc.
Here’s whether Hims & Hers Health, Inc. (HIMS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.87% over 10 days); RSI 58 — healthy momentum range; 3-month momentum positive (+42.2%). Concerns: weak 1-year return of -23.2%. Currently 48.3% off its 52-week high. Score: +5/7.
HIMS is in a confirmed uptrend, trading above both its 50-day ($32.03) and 200-day ($28.89) moving averages. An RSI of 58.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -23.2% compares to +20.5% for SPY (trailed the market by 43.6%). The current 48.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.